iifl-logo

Glenmark Life Sciences Ltd Share Price

1,111.2
(-2.91%)
May 20, 2025|03:49:20 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,149
  • Day's High1,149
  • 52 Wk High1,335.1
  • Prev. Close1,144.5
  • Day's Low1,109.2
  • 52 Wk Low 755.95
  • Turnover (lac)708.24
  • P/E28.94
  • Face Value2
  • Book Value229.8
  • EPS39.6
  • Mkt. Cap (Cr.)13,626.55
  • Div. Yield0.44
View All Historical Data
No Records Found

Glenmark Life Sciences Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,149

Prev. Close

1,144.5

Turnover(Lac.)

708.24

Day's High

1,149

Day's Low

1,109.2

52 Week's High

1,335.1

52 Week's Low

755.95

Book Value

229.8

Face Value

2

Mkt Cap (₹ Cr.)

13,626.55

P/E

28.94

EPS

39.6

Divi. Yield

0.44

Glenmark Life Sciences Ltd Corporate Action

8 May 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

5 Sep 2024

12:00 AM

AGM

Announcement Date: 05 Sep, 2024

arrow

Alivus Life Sciences Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Alivus Life Sciences Ltd SHAREHOLDING SNAPSHOT

20 May, 2025|05:15 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 74.99%

Foreign: 0.00%

Indian: 74.99%

Non-Promoter- 11.75%

Institutions: 11.75%

Non-Institutions: 13.24%

Custodian: 0.00%

Share Price

Glenmark Life Sciences Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

24.51

24.51

24.51

1.96

Preference Capital

0

0

0

0

Reserves

2,307.82

2,113.7

2,029.81

750.79

Net Worth

2,332.33

2,138.21

2,054.32

752.75

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021

Revenue

1,885.16

yoy growth (%)

Raw materials

-905.49

As % of sales

48.03

Employee costs

-149.13

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021

Profit before tax

470.94

Depreciation

-33.39

Tax paid

-119.36

Working capital

Other operating items

View Cash Flow
Y/e 31 MarMar-2021

Growth matrix (%)

Revenue growth

Op profit growth

EBIT growth

Net profit growth

View Ratios
Particulars (Rupees in Crores.)Mar-2021Mar-2020Mar-2019

Gross Sales

1,885.17

1,537.31

886.42

Excise Duty

0

0

0

Net Sales

1,885.17

1,537.31

886.42

Other Operating Income

0

0

0

Other Income

0.81

11.99

0.44

Glenmark Life Sciences Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,707.8

131.774,15,120.941,181.050.785,985.3398.33

Divis Laboratories Ltd

DIVISLAB

6,452.5

79.121,74,775.226670.452,536561.08

Cipla Ltd

CIPLA

1,454.4

24.461,20,475.721,485.41.074,254.47397.44

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,241.5

61.281,11,776.744850.852,330222.38

Mankind Pharma Ltd

MANKIND

2,549.2

54.621,05,628.36416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glenmark Life Sciences Ltd

Management

Register Office

Registrar Office

Managing Director & CEO

Yasir Yusufali Rawjee

Executive Director

Vinod Naik

Independent Non Exe. Director

Manju Agarwal

Independent Non Exe. Director

Taruvai Laxminarayanan Easwar

Chairman (Non-Executive)

HIREN KARSANBHAI PATEL

Independent Director

KAUSHIKBHAI NANDUBHAI PATEL

Independent Director

Savan Godialwala

Company Sec. & Compli. Officer

Rudalf Corriea

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Alivus Life Sciences Limited was initially established as Zorg Laboratories Private Limited, on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to Alivus Life Sciences Limited on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKlines (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL.The C
Read More

Company FAQs

What is the Alivus Life Sciences Ltd share price today?

The Alivus Life Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1111.2 today.

What is the Market Cap of Alivus Life Sciences Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd is ₹13626.55 Cr. as of 20 May ‘25

What is the PE and PB ratio of Alivus Life Sciences Ltd?

The PE and PB ratios of Alivus Life Sciences Ltd is 28.94 and 4.99 as of 20 May ‘25

What is the 52 Week High and Low of Alivus Life Sciences Ltd?

The 52-week high/low is the highest and lowest price at which a Alivus Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alivus Life Sciences Ltd is ₹755.95 and ₹1335.1 as of 20 May ‘25

What is the CAGR of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd's CAGR for 5 Years at 8.86%, 3 Years at 37.25%, 1 Year at 39.55%, 6 Month at 5.69%, 3 Month at 12.96% and 1 Month at 12.76%.

What is the shareholding pattern of Alivus Life Sciences Ltd?

The shareholding pattern of Alivus Life Sciences Ltd is as follows:
Promoters - 74.99 %
Institutions - 11.76 %
Public - 13.25 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.